Skip to main content
  • Home
  • COVID-19
  • Issues
    • Current Issue
    • All Issues
    • Online First
    • Supplement
    • CME
  • About
  • For Authors
    • Instructions for Authors
    • Submission Fee
    • Submit Manuscript
  • Podcasts

Proteinuria: Clinical Signficance and Basis for Therapy

< Back to Listing

Share this Article

Singapore Med J 2001; 42(8): 385-389
Proteinuria: Clinical Signficance and Basis for Therapy

  • Abstract
  • PDF

KT Woo, YK Lau
Correspondence: Dr K T Woo, grmwkt@sgh.com.sg

ABSTRACT
Proteinuria is the hallmark of renal disease and proteinuria exceeding 1 gm a day in patients with renal disease augers a poorer prognosis. Proteinuria has been shown to be tubulotoxic and directly contributes to renal deterioration. Patients with non-selective proteinuria are more likely to have progressive renal disease. Diabetic patients with persistent microhaematuria have about 20 times the risk of developing diabetic nephropathy. In essential hypertension, the onset of de novo proteinuria after years of adequate BP control is a marker of subsequent decline in renal function. In glomerulonephritis, more severe proteinuria is associated with faster rate of progression. Even though the initial phase of proteinuria in patients with glomerulonephritis is usually of immunological origin, in the vast majority of patients with established disease, the latter progressive phase of proteinuric glomerulopathy is the result of glomerular hyperfiltration which shifts glomerular non-selective pores to larger dimensions resulting in excessive leakage of protein in the urine. Endothelial injury resulting from glomerular hyperfiltration causes increase in local generation of Angiotensin II in the kidney as part of the hemodynamic response. ACE inhibitors and angiotensin II receptor antagonists (ATRA) can improve glomerular pore-selectivity by remodelling the glomerular basement membrane. In addition, these agents also have beneficial effects by decreasing TGF-beta production therapy decreasing mesangial cell proliferation, hence ameliorating disease progression in patients with diabetic nephropathy and IgA nephropathy. A number of recent clinical trials have shown that ACEI and ATRA therapy can retard the progression of renal deterioration in patients with NIDDM and those with IgA nephropathy and even restore normal renal function in those with mild renal impairment. Treatment and control of proteinuria in patients with renal disease should be regarded as important as treatment of hypertension as it can prevent renal failure.

Keywords: Proteinuria, Disease progression, Therapy, ACE inhibitor, Angiotensin II receptor antagonist
Singapore Med J 2001; 42(8): 385-389

http://smj.org.sg/sites/default/files/4208/4208ra1.pdf
×
POPULAR THIS MONTH
SingHealth Radiology Archives pictorial essay Part 1: cardiovascular, respiratory and neurological cases
A clinical approach to encephalopathy in children
Are migrant workers in Singapore receiving adequate healthcare? A survey of doctors working in public tertiary healthcare institutions
An approach to cervical lymphadenopathy in children

Around the Site

Home

About SMJ

For Reviewers

Sign Up for Alerts

Issues

Current Issue

All Issues

Online First

Supplement

CME

For Authors

Instructions for Authors

Submit Manuscript


Follow us on:
    

More Links

Contact Us

Copyright

Advertise

SMJ Forms

Privacy Policy

SMA Home

Copyright 2021. Singapore Medical Association. All Rights Reserved.